J Hematol . COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma

[tetano]

J Hematol


. 2022 Apr;11(2):77-80.
doi: 10.14740/jh845. Epub 2022 Apr 22.
COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma


Daniele Colombo ¹ , Arianna Gatti ² , Patrizia Alabardi ¹ , Daniela Bompane ¹ , Giorgio Bonardi ¹ , Nicola Mumoli ³ , Paola Faggioli ¹ , Pierangelo Clerici ² , Bruno Brando ² , Antonino Mazzone ¹



Affiliations

• PMID: 35573753
• PMCID: PMC9076145
• DOI: 10.14740/jh845

Abstract

Coronavirus disease 2019 (COVID-19) can have a severe course in immunocompromised hosts and patients with hematological malignancies. In some cases, the bad prognosis is associated with the lack of B lymphocytes, with impaired antibody production and inefficient viral clearance. We report a case of a 67-year-old woman with a story of non-Hodgkin lymphoma treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), who got a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while being totally depleted of B cells. This condition has determined a severe and prolonged course of COVID-19, with persistently positive nasopharyngeal molecular swabs and lack of anti-SARS-CoV-2 specific antibodies. The clinical recovery was favored by the administration of convalescent hyperimmune plasma.

Keywords: Anti-SARS-CoV-2 antibodies; COVID-19; Convalescent plasma; Rituximab; SARS-CoV-2 swab.